Form 8-K - Current report:
SEC Accession No. 0001193125-26-117794
Filing Date
2026-03-20
Accepted
2026-03-20 16:45:07
Documents
11
Period of Report
2026-03-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d122428d8k.htm   iXBRL 8-K 29477
  Complete submission text file 0001193125-26-117794.txt   144159

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20260316.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20260316_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20260316_pre.xml EX-101.PRE 11262
14 EXTRACTED XBRL INSTANCE DOCUMENT d122428d8k_htm.xml XML 3653
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 26778807
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)